Supplementary Table 1: Primers for CNV Validation

Supplementary Table 1: Primers for CNV Validation

<p>Supplementary Table 2: Full list of high stringency genic CNV calls (2 or more algorithms), with no overlapping calls in 2,357 POPGEN and OHI controls, and <50% overlap in DGV. Coordinates refer to Human Genome Build36/hg18. Algorithms used include iPattern (IPN), Genotyping Console (GTC) and BirdSuite (BS). CNVs validated by qPCR are indicated by bold type. Ancestry is European unless otherwise stated in the footnotes. A list of all calls, including lower stringency calls is available from the corresponding author.</p><p>ID Cytoband Start Stop Size C Algorithms # of Probes Genes MIM #; N Associated V pathology</p><p>A217# 1q24.3 170,174,1 170,226,179 52,069 g BS,IPN|GTC 41 DNM3 11 a i n</p><p>A217# 1q31.3 195,206,3 195,222,522 16,181 L BS,IPN|GTC 19 CFHR5 61480;neph 42 o ropathy s s</p><p>A86 1q41 218,154,6 218,179,823 25,154 G BS,IPN 18 SLC30A10 613280; 70 a hypermanga i n- esemia n with dystonia, polycythem ia & cirrhosis</p><p>A62 2p25.1 10,208,86 10,474,077 265,213 L BS,IPN|GTC 213 HPCAL1,C2orf48 5 o s s</p><p>A187 2p23.3 25,717,73 25,777,692 59,958 g BS,IPN|GTC 33 DTNB 5 a i n</p><p>A156 2q21.2 133,600,5 133,728,969 128,442 L BS,IPN|GTC 90 NCKAP5 28 o s s</p><p>A116 3p25.3 11,451,72 11,466,305 14,578 L BS,IPN|GTC 17 ATG7 * 8 o s s</p><p>A200 3p24.3 17,655,22 17,758,388 103,168 L BS,IPN|GTC 45 TBC1D5 1 o s s</p><p>A204 3q21.1 124,907,3 124,956,275 48,946 L BS,IPN|GTC 28 MYLK 613780; 30 o familial s thoracic s aortic aneuysm 7</p><p>A27 3q25.32 158,558,2 158,639,900 81,619 G BS,IPN|GTC 57 VEPH1,PTX3 82 a i n</p><p>A184 3q28 192,624,9 192,672,766 47,867 L BS,IPN|GTC 37 PYDC2 00 o s s</p><p>A217 3q28 193,415,1 193,427,820 12,628 G BS,IPN|GTC 35 FGF12 93 a i n</p><p>A217 3q28 193,430,5 193,452,431 21,886 L BS,IPN|GTC 16 FGF12 46 o s s</p><p>A6 4p12 47,881,69 47,910,404 28,706 L BS,IPN|GTC 86 TEC 9 o s s</p><p>A213 5q12.3 63,974,15 64,240,025 265,870 G BS,IPN|GTC 143 FAM159B,CWC27,SREK1IP1 6 a i n</p><p>A23 6p25.1 5,170,870 5,308,007 137,138 L BS,IPN|GTC 95 FARS2,LYRM4 614946 o (FARS2) ; s Combined s oxidative phosphoryla tion deficiency 14</p><p>A44 6p24.1,6p24.2 11,192,62 11,233,071 40,449 L BS,IPN|GTC 23 LOC221710,HERV-FRD 3 o s s</p><p>A196 6p22.3 17,763,62 17,862,652 99,029 G BS,IPN|GTC 54 NUP153 4 a i n</p><p>A83 6q15 88,234,01 88,350,126 116,111 G BS,IPN|GTC 62 SLC35A1,RARS2 603585 6 a (SLC35A1) i ; n Congenital disorder of glycosylati on, type IIf</p><p>A50 7q11.22 68,391,49 68,846,056 454,564 G BS,IPN|GTC 235 AUTS2 607373; 3 a autism i susceptibilit n y 8</p><p>A103 7q35 145,687,3 145,707,079 19,727 L BS,IPN|GTC 19 CNTNAP2 610042; 53 o cortical s dysplasia- s focal epilepsy syndrome; Pitt- Hopkins Like syndrome1;</p><p>612100; autism susceptibilit y 15</p><p>A210 7q36.2 152,909,7 153,711,379 801,622 G BS,IPN|GTC 571 DPP6 612956; 58 a Ventricular i fibrillation, n paroxysmal familial, 2 A35$ 7q36.2 153,462,8 153,529,856 67,048 L BS,IPN|GTC 38 DPP6 09 o s s</p><p>A41 8p23.1 9,948,345 9,980,334 31,990 L BS,IPN|GTC 28 MSRA o s s</p><p>A196 9p11.2-q12 45,506,51 65,370,766 19.9Mb L BS|GTC 55 FAM75A5,FAM75A7,FAM74A4,FAM7 6 o 4A2,FAM27A,KGFLP1 s s</p><p>A32 10p14 8,021,446 8,034,890 13,445 L BS,IPN 14 TAF3 o s s</p><p>A67% 10p11.21 35,393,77 35,496,363 102,593 L BS,IPN|GTC 45 CREM,CUL2 1 o s s</p><p>A67 10q22.1 74,184,90 74,230,349 45,445 L BS,IPN|GTC 26 CCDC109A 5 o s s</p><p>A210 11p14.1 28,105,47 28,135,299 29,828 L BS,IPN|GTC 17 METTL15 2 o s s</p><p>A196 11q13.4 73,617,08 73,947,977 330,895 G BS,IPN|GTC 230 P4HA3,PPME1,KCNE3,LIPT2,PGM2L1 3 a i n</p><p>A21 11q14.1 83,108,46 83,378,706 270,241 G BS,IPN|GTC 208 DLG2 6 a i n</p><p>A16 12q24.11 108,087,8 108,127,535 39,659 L BS,IPN|GTC 28 ACACB 77 o s s</p><p>A136 12q24.22 115,655,3 115,797,029 141,658 G BS,IPN|GTC 89 C12orf49,RNFT2,HRK 72 a i n</p><p>A213 12q24.33 130,105,7 130,333,801 228,008 G BS,IPN|GTC 187 LOC116437,GPR133 94 a i n</p><p>A94 13q21.33 69,452,46 69,471,066 18,606 L BS,IPN|GTC 11 KLHL1 1 o s s</p><p>A182 14q23.3 66,274,49 66,631,750 357,252 l BS,IPN|GTC 142 GPHN 252150; 9 o Molybdenu s m cofactor s deficiency, type C</p><p>A83 14q31.1 78,548,11 78,587,995 39,879 L BS,IPN|GTC 35 NRXN3 7 o s s</p><p>A187 14q32.33 103,116,8 103,151,310 34,436 l BS,IPN|GTC 16 C14orf153 (APOPT1) 75 o s s</p><p>A23 15q21.3 52,531,91 52,555,069 23,155 L BS,IPN|GTC 16 UNC13C 5 o s s</p><p>A136 16p11.2 28,660,95 28,951,376 290,425 L BS,IPN|GTC 77 ATXN2L,ATP2A1,NFATC2IP,SPNS1, 613444; 2 o RABEP2,SH2B1,LAT,TUFM,CD19 16p11.2 s deletion s syndrome (220Kb);</p><p>601003 (ATP2A1); Brody myopathy;</p><p>610678 (TUFM); Combined oxidative phosphoryla tion deficiency 4;</p><p>613493 (CD19); Immunodefi ciency, common variable, 3</p><p>A67 16q12.1 47,911,71 48,519,007 607,296 G BS,IPN|GTC 456 C16orf78,ZNF423 614844 2 a (ZNF423); i Joubert n syndrome 19, Nephronop hthisis 14</p><p>A217# 17p12 12,238,67 12,985,028 746,356 g BS,IPN|GTC 563 ARHGAP44,MYOCD,FLJ34690,ELAC2 614731 3 a (ELAC2); i susceptibilit n y to hereditary prostate cancer 2</p><p>A44 17q21.31 39,578,59 39,756,006 177,413 G BS,IPN|GTC 77 C17orf65,ASB16,TMUB2,SLC25A39,U 179800 4 a BTF,RUNDC3A,SLC4A1,C17orf53,AT (SLC4A1); i XN7L3 Renal n tubular acidosis, distal, AD A162 17q23.3 58,985,82 58,999,732 13,908 l BS,IPN|GTC 11 DCAF7 5 o s s</p><p>A196 17q24.3 68,081,13 68,107,879 26,743 g IPN|GTC 18 FLJ26484,LOC100499467 7 a i n</p><p>A196 17q24.3 68,143,01 68,212,703 69,690 g BS,IPN|GTC 69 FLJ26484,SLC39A11 4 a i n</p><p>A79 17q25.3 74,912,21 75,225,624 313,407 G BS,IPN|GTC 81 hCG_1776007 8 a i n</p><p>A144 18q23 75,895,79 75,956,745 60,948 G BS,IPN|GTC 43 C18orf22 8 a i n</p><p>A153 18q23 75,895,79 75,956,745 60,948 G BS,IPN|GTC 43 C18orf22 8 a i n</p><p>A161 19p13.2 11,891,25 11,922,384 31,127 G BS,IPN 24 ZNF700 8 a i n</p><p>A62 21q22.11 31,680,65 31,991,168 310,512 G BS,IPN|GTC 201 TIAM1,SFRS15,SOD1 105400 7 a (SOD1); i Amyotrophi n c lateral sclerosis 1</p><p>A150a Xp22.11,Xp21.3 24,513,97 27,864,451 3,350,473 G BS,IPN|GTC 2105 MAGEB18,POLA1,PCYT1B,ARX,VE 310465 9 a NTXP1,SMEK3P,MAGEB10,MAGEB (POL1); N i 6,SCARNA23,DCAF8L2 syndrome; n 300419 (ARX); Mental retardation, X-linked 29 and others</p><p>A38b& Xq13.1 68,811,63 68,873,651 62,021 G BS,IPN|GTC 39 EDA 313500; 1 a Tooth i agenesis, n selective, X-linked 1</p><p>305100; Ectodermal dysplasia 1, hypohidroti c, X-linked</p><p>A67b Xq23 111,485,5 112,035,904 550,371 G BS,IPN|GTC 329 AMOT,ZCCHC16,LHFPL1 34 a i n aproband is male bproband is female</p><p>%:qPCR was attempted but was unable to validate this CNV</p><p>#:father from Pakistan, mother from Austria *: Ugandan</p><p>$:Egyptian</p><p>&: Turkish</p>

View Full Text

Details

  • File Type
    pdf
  • Upload Time
    -
  • Content Languages
    English
  • Upload User
    Anonymous/Not logged-in
  • File Pages
    8 Page
  • File Size
    -

Download

Channel Download Status
Express Download Enable

Copyright

We respect the copyrights and intellectual property rights of all users. All uploaded documents are either original works of the uploader or authorized works of the rightful owners.

  • Not to be reproduced or distributed without explicit permission.
  • Not used for commercial purposes outside of approved use cases.
  • Not used to infringe on the rights of the original creators.
  • If you believe any content infringes your copyright, please contact us immediately.

Support

For help with questions, suggestions, or problems, please contact us